38 completed, 6 recruiting, 5 active not recruiting, 3 enrolling by invitation. 21 Phase 3, 9 Phase 2, 5 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Hereditary Angioedema (HAE): new trials by email Literature Review of Hereditary Angioedema (HAE) trials Research Report on Hereditary Angioedema (HAE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt No intervention - Hereditary Angioedema (HAE) | Not yet recruiting | Takeda | 100 | 2026-12-01 | 2026-06-18 | |
| A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 35 | 2026-09-21 | 2026-10-15 | |
| A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema Technochrom C1-INH Kit - Hereditary Angioedema (HAE) | Not applicable | Recruiting | Takeda | 514 | 2026-05-12 | 2026-05-19 |
| A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 50 | 2026-04-30 | 2026-05-11 | |
| Donidalorsen Treatment in Children With Hereditary Angioedema Donidalorsen - Hereditary Angioedema (HAE) | Phase 3 | Recruiting | Ionis Pharmaceuticals, Inc. | 20 | 2026-04-21 | 2026-09-02 |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) ADX-324 Dose Level 1, ADX-324 Dose Level 2 - Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2026-04-02 | 2026-09-04 |
| A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries No intervention - Hereditary Angioedema (HAE) | Completed | Takeda | 37 | 2026-02-05 | 2026-07-14 | |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| A Study of Navenibart in Participants With Hereditary Angioedema navenibart, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Astria Therapeutics, Inc. | 157 | 2025-03-20 | 2026-06-30 |
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| Suicide Ideation in Hereditary Angioedema Hereditary Angioedema (HAE), Suicidal Ideation | Not yet recruiting | Ivan Cherrez Ojeda | 100 | 2025-03-01 | 2025-02-10 | |
| HAE Burden and Crisis Management Hereditary Angioedema (HAE) | Completed | University Hospital, Grenoble | 300 | 2025-03-01 | 2026-04-29 | |
| A Phase 2 in Adult Subjects With Hereditary Angioedema BW-20805 - Hereditary Angioedema (HAE) | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 25 | 2025-02-28 | 2026-04-17 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Pharvaris Netherlands B.V. | 81 | 2024-12-01 | 2026-02-13 |
| A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People No Intervention - Hereditary Angioedema (HAE) | Completed | Takeda | 19 | 2024-10-16 | 2025-02-10 | |
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China No intervention - Hereditary Angioedema (HAE) | Completed | Takeda | 115 | 2024-07-20 | 2026-01-21 | |
| A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) No Intervention - Hereditary Angioedema (HAE) | Active not recruiting | Takeda | 50 | 2023-06-29 | 2025-11-20 | |
| A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada No Intervention - Hereditary Angioedema (HAE), Angioedema | Completed | Takeda | 60 | 2023-06-15 | 2024-07-30 |
Showing 20 of 57. Sign in to see all of them.
Angioedemas, Hereditary (57) · Angioedema (6) · Cardiovascular Diseases (1) · Genetic Diseases, Inborn (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Skin Diseases (1) · Skin Diseases, Vascular (1) · Suicidal Ideation (1) · Urticaria (1) · Vascular Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (57) · Hereditary Complement Deficiency Diseases (57) · Immunologic Deficiency Syndromes (57) · Primary Immunodeficiency Diseases (57) · Skin and Connective Tissue Diseases (57) · Cardiovascular Diseases (56) · Genetic Diseases, Inborn (56) · Hypersensitivity (56) · Hypersensitivity, Immediate (56) · Immune System Diseases (56) · Skin Diseases (56) · Skin Diseases, Vascular (56) · Urticaria (56) · Vascular Diseases (56) · Angioedema (51)
lanadelumab (8) · ecallantide (6) · icatibant (6) · Complement C1 Inhibitor Protein (3) · SERPING1 protein, human (3) · berotralstat (2) · Fluid Therapy (1) · IONIS-PKK-LRx (1) · Syringes (1) · conestat alfa (1) · donidalorsen (1)
Shire (26) · Takeda (15) · Pharvaris Netherlands B.V. (3) · Astria Therapeutics, Inc. (2) · BioCryst Pharmaceuticals (2) · CSL Behring (2) · ADARx Pharmaceuticals, Inc. (1) · Institute for Asthma and Allergy (1) · Ionis Pharmaceuticals, Inc. (1) · Ivan Cherrez Ojeda (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · Shanghai Argo Biopharmaceutical Co., Ltd. (1) · University Hospital, Grenoble (1)
United States (27) · Germany (23) · Canada (17) · Italy (16) · Spain (16) · United Kingdom (15) · France (12) · Israel (12) · Hungary (11) · Japan (11) · Austria (10) · Poland (10) · Australia (9) · Puerto Rico (7) · Brazil (6)
Hilary Longhurst, MBBS, PhD (1) · Lauge Farnaes, MD (1) · Markus Magerl, Doctor (1)
PMID 36326435, PMID 23878046, PMID 24712435, PMID 23548529, PMID 21130380, PMID 22765833, PMID 23548526, PMID 36153561, PMID 36408587, PMID 37028510, PMID 40171989, PMID 40769455, PMID 20818887, PMID 24980392, PMID 25198193, PMID 26112099, PMID 26171584, PMID 26314822, PMID 27116379, PMID 27742086, PMID 27931305, PMID 28225674, PMID 28601641, PMID 28662509, PMID 28690642, PMID 29043014, PMID 29599966, PMID 30044938, PMID 30127805, PMID 30480729, PMID 30682573, PMID 30968444, PMID 34287942, PMID 34965883, PMID 35861129, PMID 39128590, PMID 39701274, PMID 40504359, PMID 41566486, PMID 41818404, PMID 42630033
2015 (2), 2023 (1), 2025 (1)